A pre-specified VESALIUS-CV analysis found evolocumab cut all-cause death by 20% in high-risk primary prevention, with the benefit appearing only after 1.5 years and a 1.8-point absolute gap at five years.
Newsletter
Pipeline, markets, policy, and science. Once a week.
After encouraging early pancreatic data, demand for Alpha DaRT helped quadruple its IMPACT study from 12 patients to 48 as the company moves toward a pivotal trial.
Conjugating antisense oligonucleotides to transferrin receptor transport vehicles achieves fifty-fold deeper brain penetration, challenging the standard of invasive spinal punctures.
A 25 August Nature Biomedical Engineering paper shows malignant synapses concentrated at the GBM-brain interface, then tests an intracavitary TrkB-silencing hydrogel that more than doubled median survival in a mouse resection model.